智通财经APP讯,荃信生物-B(02509)发布公告,配售协议所载的所有条件已获达成,而配售事项完成已根据配售协议的条款于2025年8月25日落实。
根据配售协议的条款及条件,配售代理已成功按配售价每股配售股份20.0港元向一名承配人(即TruMed Health Innovation Fund LP)配售合共500万股配售股份,占(i)紧接配售事项完成前已发行股份数目约2.25%;及(ii)紧随配售事项完成后经配发及发行配售股份扩大后的已发行股份数目约2.20%。
智通财经APP讯,荃信生物-B(02509)发布公告,配售协议所载的所有条件已获达成,而配售事项完成已根据配售协议的条款于2025年8月25日落实。
根据配售协议的条款及条件,配售代理已成功按配售价每股配售股份20.0港元向一名承配人(即TruMed Health Innovation Fund LP)配售合共500万股配售股份,占(i)紧接配售事项完成前已发行股份数目约2.25%;及(ii)紧随配售事项完成后经配发及发行配售股份扩大后的已发行股份数目约2.20%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.